Fresenius Medical Care ( (FMS) ) has released its Q2 earnings. Here is a breakdown of the information Fresenius Medical Care presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fresenius Medical Care AG is a leading global provider of products and services for individuals with chronic kidney failure, operating primarily in the healthcare sector with a focus on dialysis care and related services.
In its latest earnings report for the second quarter and first half of 2025, Fresenius Medical Care reported modest revenue growth, alongside a significant increase in net income attributable to shareholders, reflecting the company’s strategic focus on operational efficiency and cost management.
The company’s total revenue for the first half of 2025 increased by 1.9% to €9,673 million, with a notable 28.7% rise in net income to €463 million. The Care Delivery segment experienced a slight revenue decline, while the Value-Based Care segment saw a substantial 23.5% increase. Operating income, excluding special items, rose by 11.2% to €933 million, indicating improved operational performance.
Fresenius Medical Care’s balance sheet showed a decrease in total assets to €31,291 million, with a slight reduction in total equity. The company’s free cash flow after investing activities increased significantly, demonstrating strong cash management and liquidity.
Looking ahead, Fresenius Medical Care anticipates positive revenue growth in 2025, with operating income expected to grow at a high-teens to high-twenties percentage rate, driven by ongoing strategic initiatives and market expansion efforts.